Didier Leclercq is Aerolase’s new Vice President of Global Market Development.
Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by Galderma, with the Q-Med portfolio including leading injectables such as Restylane filler and Dysport toxin.
"It is exciting to join Aerolase as VP of Global Market Development. Over the years I have come to respect Aerolase as a significant innovator and emerging force in the dermatology and aesthetic field. In fact, it was the only laser we saw fit to feature at the SHIELD innovation center," says Leclercq. "The Aerolase portability combined with top efficacies in multiple key derm treatment areas makes it a unique and powerful device range.”
"Didier brings a rich array of expertise which will accelerate our path to industry leadership based on Aerolase' commitment to excellence in laser skin health," says Pavel Efremkin PhD, Chairman and CEO of Aerolase, in a news release. "His background in aesthetic injectables and pharmaceuticals is an ideal complement to our high innovation position in dermatology lasers, as we incorporate our gold standard devices into powerful combo therapy protocols in concert with toxins, fillers and medications."